Associations between biomarkers of multimorbidity burden and mortality risk among patients with acute dyspnea
Tóm tắt
The patients’ burden of comorbidities is a cornerstone in risk assessment, clinical management and follow-up. The aim of this study was to evaluate if biomarkers associated with comorbidity burden can predict outcome in acute dyspnea patients. We included 774 patients with dyspnea admitted to an emergency department and measured 80 cardiovascular protein biomarkers in serum collected at admission. The number of comorbidities for each patient were added, and a multimorbidity score was created. Eleven of the 80 biomarkers were independently associated with the multimorbidity score and their standardized and weighted values were summed into a biomarker score of multimorbidities. The biomarker score and the multimorbidity score, expressed per standard deviation increment, respectively, were related to all-cause mortality using Cox Proportional Hazards Model. During long-term follow-up (2.4 ± 1.5 years) 45% of the patients died and during short-term follow-up (90 days) 12% died. Through long-term follow-up, in fully adjusted models, the HR (95% CI) for mortality concerning the biomarker score was 1.59 (95% CI 1348–1871) and 1.18 (95% CI 1035–1346) for the multimorbidity score. For short-term follow-up, in the fully adjusted model, the biomarker score was strongly related to 90-day mortality (HR 1.98, 95% CI 1428–2743), whereas the multimorbidity score was not significant. Our main findings suggest that the biomarker score is superior to the multimorbidity score in predicting long and short-term mortality. Measurement of the biomarker score may serve as a biological fingerprint of the multimorbidity score at the emergency department and, therefore, be helpful for risk prediction, treatment decisions and need of follow-up both in hospital and after discharge from the emergency department.
Tài liệu tham khảo
DeVos E, Jacobson L (2016) Approach to adult patients with acute dyspnea. Emerg Med Clin N Am 34(1):129–149
Roger VL (2013) Epidemiology of heart failure. Circ Res 113(6):646–659
Kelly AM, Keijzers G, Klim S, Graham CA, Craig S, Kuan WS et al (2017) An observational study of dyspnea in Emergency Departments: The Asia, Australia, and New Zealand Dyspnea in Emergency Departments Study (AANZDEM). Acad Emerg Med 24(3):328–336
Guder G, Stork S (2019) COPD and heart failure: differential diagnosis and comorbidity. Herz 44(6):502–508
Widgren BR, Jourak M (2011) Medical Emergency Triage and Treatment System (METTS): a new protocol in primary triage and secondary priority decision in emergency medicine. J Emerg Med 40(6):623–628
(NYHA) TNYHA (1994) Classes of Heart Failure. Functional Classification Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edn. Lippincott Williams and Wilkins, Boston
Wessman TTR, Ruge T, Melander O (2021) Socioeconomic and clinical predictors of mortality in patients with acute dyspnea. Open Access Emerg Med 2021(13):107–116
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Brusselaers N, Lagergren J (2017) The Charlson Comorbidity Index in Registry-based Research. Methods Inf Med 56(5):401–406
Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27
Molto A, Dougados M (2014) Comorbidity indices. Clin Exp Rheumatol 32(5 Suppl 85):S-131-4
Alonso-Moran E, Nuno-Solinis R, Onder G, Tonnara G (2015) Multimorbidity in risk stratification tools to predict negative outcomes in adult population. Eur J Intern Med 26(3):182–189
Diederichs C, Berger K, Bartels DB (2011) The measurement of multiple chronic diseases–a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci 66(3):301–311
Feldreich T, Nowak C, Fall T, Carlsson AC, Carrero JJ, Ripsweden J et al (2019) Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. J Nephrol 32(1):111–119
Nowak C, Carlsson AC, Ostgren CJ, Nystrom FH, Alam M, Feldreich T et al (2018) Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia 61(8):1748–1757
Lind L, Arnlov J, Lindahl B, Siegbahn A, Sundstrom J, Ingelsson E (2015) Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 242(1):205–210
Stenemo M, Nowak C, Byberg L, Sundstrom J, Giedraitis V, Lind L et al (2018) Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 20(1):55–62
Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, Rahimi HR, Tajfard M, Ferns G (2018) Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice. J Cell Physiol 233(11):8508–8525